The fight against cancer is often framed as a battle of biological innovation, focusing on the latest immunotherapies, surgical techniques, and genomic mapping. However, behind every breakthrough lies a foundation of data—a silent but essential infrastructure that tracks who is getting sick, where they live, and how they respond to treatment. At the heart of this infrastructure are America’s Cancer Registries.
Recently, METAvivor, a leading non-profit organization dedicated to funding research for Stage IV metastatic breast cancer (MBC), took a definitive stand to protect this infrastructure. The organization has officially weighed in on the federal budget process, urging the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies to prioritize and increase funding for cancer surveillance programs as they set levels for the 2027 fiscal year.
This move underscores a critical reality in oncology: without robust, well-funded data collection, the medical community is essentially fighting an invisible enemy with one hand tied behind its back.
Main Facts: The Pillars of Cancer Surveillance
The advocacy efforts led by METAvivor focus specifically on two vital programs: the Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries (NPCR) and the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
The Role of NPCR and SEER
The NPCR and SEER programs together cover 100% of the U.S. population. The NPCR, established in 1992, supports state-based registries that collect data on cancer occurrence, including the type, extent, and location of the cancer, as well as the type of initial treatment. Meanwhile, the SEER program, which began in 1973, provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population.
METAvivor’s Intervention
METAvivor’s recent letter to the Senate Appropriations Subcommittee is a proactive measure. While 2027 may seem distant to the general public, the federal appropriations process involves long-term planning. By intervening now, METAvivor aims to ensure that the momentum gained in cancer research over the last decade is not lost due to administrative budget cuts or inflationary erosion of resources.
The organization’s primary argument is that these registries are not merely "record-keeping" tools; they are the "radar" of the national cancer strategy. For the metastatic community—those living with cancer that has spread from the primary site to distant organs—this data is life or death. Historically, metastatic patients have been undercounted, as registries often only recorded the initial diagnosis. METAvivor is advocating for funding that allows these registries to modernize and capture recurrence and metastatic progression.
Chronology: The Evolution of Cancer Data Advocacy
The journey toward comprehensive cancer tracking in the United States has been a decades-long endeavor, marked by legislative milestones and shifting medical priorities.
1971–1973: The Foundation
The National Cancer Act of 1971, signed by President Richard Nixon, catalyzed the "War on Cancer." This led to the establishment of the SEER program in 1973. Initially, SEER focused on a few geographic areas to provide a representative sample of the U.S. population.
1992: Expanding the Scope
Recognizing that SEER did not cover the entire country, Congress passed the Cancer Registries Amendment Act in 1992, which established the NPCR. This allowed the CDC to provide funds to states and territories to enhance their existing registries or create new ones.
2009–2015: The Rise of Patient Advocacy
During this period, organizations like METAvivor began to gain national prominence. They highlighted a glaring gap in the data: the "Lost Population." Registries were excellent at tracking new cases of cancer, but if a patient’s breast cancer returned as metastatic five years after their initial "cure," that recurrence was often not captured in national statistics.
2020–2024: Modernization and the "Recount" Movement
In recent years, the focus has shifted toward the "Modernization of Cancer Registries." Legislative efforts have pushed for the integration of Electronic Health Records (EHR) into the registry system. METAvivor has been at the forefront of the "Recount" movement, demanding that the NCI and CDC develop better methods to track metastatic recurrence specifically.
2024: The 2027 Funding Push
In late 2024, METAvivor initiated its current campaign for the 2027 budget. By sending formal communications to the Senate Appropriations Subcommittee, they are positioning cancer data as a non-negotiable priority in the upcoming federal budget cycles.
Supporting Data: Why Registries Matter
To understand why METAvivor is fighting so hard for registry funding, one must look at the data—and the gaps within it.
The Metastatic Burden
It is estimated that over 168,000 women in the U.S. are living with metastatic breast cancer. However, because national registries have historically focused on incidence (new cases) rather than prevalence (total people living with the disease), this number is often cited as an estimate rather than a hard fact. Accurate funding for NPCR and SEER would allow for more precise tracking of these patients, leading to better allocation of healthcare resources.
The Cost of Inaccuracy
Without accurate registry data, researchers cannot identify "hotspots" of cancer or determine if certain demographics are being disproportionately affected by metastatic disease. Data from the CDC suggests that cancer registries help identify areas where screening rates are low or where environmental factors may be contributing to higher cancer rates.
The Impact of Federal Funding
Currently, the NPCR receives roughly $50 million to $60 million annually to support registries across nearly every state. While this sounds substantial, when spread across 50 states, it barely covers the cost of basic data entry and quality control. METAvivor argues that a significant increase is required to transition these registries into the digital age, utilizing AI to scrape data from pathology reports and clinical notes automatically.
Official Responses: The Call for Sustainable Investment
The response from the advocacy community has been one of unified urgency. In the letter addressed to the Senate Appropriations Subcommittee, METAvivor emphasized that "consistent and strong support for these registries is essential in our fight against cancer."
The Advocacy Position
METAvivor’s leadership maintains that the CDC and NCI are currently hamstrung by "flat-funding" cycles. When budgets do not account for inflation or the rising cost of data security and technology, it results in a functional "cut" to the programs. Their letter calls for a "robust increase" that reflects the growing complexity of cancer care.
Legislative Sentiment
While the Senate Appropriations Subcommittee has not yet released its formal 2027 framework, members of the subcommittee have historically expressed bipartisan support for the NCI and CDC. However, the challenge lies in the competition for federal dollars. By mobilizing early, METAvivor is ensuring that cancer surveillance isn’t sidelined by other emerging public health crises.
Professional Medical Community
The North American Association of Central Cancer Registries (NAACCR) has echoed METAvivor’s sentiments. Medical professionals argue that registries are the only way to measure the "Return on Investment" (ROI) of federal research dollars. If the government spends billions on new drugs but has no data to see if those drugs are extending lives on a national scale, the investment cannot be fully evaluated.
Implications: What is at Stake?
The implications of the funding levels set for 2027 will be felt for decades. The decisions made by Congress today will determine the quality of cancer care for the next generation.
1. Health Equity
One of the most significant implications of robust registry funding is the ability to address health disparities. Comprehensive data allows policymakers to see where racial and socioeconomic gaps exist in cancer survival. Without this data, "Moonshot" initiatives to end cancer will fail to reach the most vulnerable populations.
2. Personalized Medicine
The future of oncology is personalized medicine—tailoring treatment to the specific genetic makeup of a patient’s tumor. Registries are increasingly being used to link clinical data with genomic data. If funding for NPCR and SEER is stagnant, the U.S. risks falling behind in the global race to develop precision oncology.
3. The "Recount" and Metastatic Research
For the METAvivor community, the primary implication is visibility. For too long, the metastatic community has felt "erased" by statistics that focus on five-year survival rates and "cures." Accurate registry data will finally provide a clear picture of the metastatic landscape, which in turn will drive more pharmaceutical interest and federal research grants toward Stage IV treatments.
4. Economic Impact
Cancer is an immense drain on the U.S. economy, both in terms of healthcare costs and lost productivity. Effective surveillance allows for more efficient healthcare spending. By identifying what treatments work in the real world (outside of controlled clinical trials), registries help the healthcare system pivot toward high-value care.
Conclusion
METAvivor’s advocacy for the 2027 CDC and NCI funding levels is a reminder that the "War on Cancer" is fought on many fronts. While the laboratory and the clinic are the most visible battlegrounds, the halls of Congress and the databases of cancer registries are where the strategy is formed and the progress is measured.
As the Senate Appropriations Subcommittee begins its deliberations, the message from the metastatic community is clear: Data is not just numbers; it is the collective voice of patients. To ignore the registries is to ignore the patients themselves. The call for "consistent and strong support" is a call for a future where no cancer patient is uncounted, and no recurrence is overlooked.
For those following the legislative process, the full letter sent by METAvivor serves as a roadmap for what modern cancer surveillance should look like—a system that is as dynamic, resilient, and determined as the patients it tracks.
About the Author
